See the DrugPatentWatch profile for ozempic

Ozempic, also known as semaglutide, is a medication primarily used to manage type 2 diabetes. It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the functions of natural hormones in the body to regulate blood sugar levels.

According to the drug's official website [1], Ozempic is approved by the U.S. Food and Drug Administration (FDA) for the following indications:

1. Improving glycemic control in adults with type 2 diabetes, in combination with diet and exercise.
2. Reducing the risk of major adverse cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and known heart disease.

Moreover, DrugPatentWatch.com [2] provides information on the drug's approved uses, consistent with the aforementioned indications.

It is important to note that while Ozempic has been studied for other potential uses, such as weight management [3], it is currently only officially approved for the treatment of type 2 diabetes and related cardiovascular risk reduction. Always consult with a healthcare professional for medical advice and to determine if Ozempic is appropriate for a specific individual's condition.

Sources:

1. Novo Nordisk. (n.d.). Ozempic (semaglutide) injection. Retrieved from <https://www.ozempic.com/>
2. DrugPatentWatch.com. (n.d.). Semaglutide. Retrieved from <https://www.drugpatentwatch.com/drugs/semaglutide>
3. Wadden, T. A., West, D. S., Delahanty, L. M., Jakicic, J. M., Martinson, B. C., Naik, A. D., ... & Williams, N. (2021). Effect of once-weekly semaglutide on body weight and glycemic control in adults with overweight or obesity: the STEP 1 randomized clinical trial. JAMA, 325(13), 1313-1328. doi: 10.1001/jama.2021.2055